Literature DB >> 18313838

Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation.

Olorunseun O Ogunwobi1, Ian L P Beales.   

Abstract

Obesity increases the risk of developing several cancers including oesophageal adenocarcinoma (OAC). Obesity is characterised by hyperleptinaemia and hypoadiponectinaemia: we have hypothesised that these hormonal factors may contribute to the progression of OAC. We have examined the effects of leptin and adiponectin on proliferation of OAC cells. Leptin-stimulated proliferation in four different OAC lines (OE33, OE19, BIC-1 and FLO) and this was inhibited by globular but not full length adiponectin. All four OAC lines expressed both adiponectin-receptor isoforms (AdipoR1 and AdipoR2). Globular adiponectin also inhibited leptin-induced proliferation in rat IEC-18 cells which only expressed AdipoR1. Specific inhibitors of 5'-AMP-activated protein kinase (Compound C) and serine/threonine phosphatases (okadaic acid) and a specific siRNA to AdipoR1 blocked the anti-proliferative effects of adiponectin. Adiponectin inhibited leptin-induced Akt phosphorylation; this action was sensitive to okadaic acid but not to Compound C. Adiponectin deficiency may contribute to the promotion of OAC in obesity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313838     DOI: 10.1016/j.mce.2008.01.023

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  36 in total

Review 1.  The role of obesity in oesophageal cancer development.

Authors:  Elizabeth Long; Ian L P Beales
Journal:  Therap Adv Gastroenterol       Date:  2014-11       Impact factor: 4.409

2.  Serum leptin and adiponectin levels and risk of Barrett's esophagus and intestinal metaplasia of the gastroesophageal junction.

Authors:  Olivia M Thompson; Shirley A A Beresford; Elizabeth A Kirk; Mary P Bronner; Thomas L Vaughan
Journal:  Obesity (Silver Spring)       Date:  2010-01-28       Impact factor: 5.002

3.  Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.

Authors:  Ian L P Beales; Leanne Dearman; Inna Vardi; Yoon Loke
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

Review 4.  Association of Serum Levels of Adipokines and Insulin With Risk of Barrett's Esophagus: A Systematic Review and Meta-Analysis.

Authors:  Apoorva Krishna Chandar; Swapna Devanna; Chang Lu; Siddharth Singh; Katarina Greer; Amitabh Chak; Prasad G Iyer
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-15       Impact factor: 11.382

5.  Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease.

Authors:  Lucy M Almers; James E Graham; Peter J Havel; Douglas A Corley
Journal:  Clin Gastroenterol Hepatol       Date:  2015-01-26       Impact factor: 11.382

Review 6.  Adiponectin and breast cancer.

Authors:  Xiuping Chen; Yitao Wang
Journal:  Med Oncol       Date:  2010-07-13       Impact factor: 3.064

7.  Adiponectin modulates DCA-induced inflammation via the ROS/NF-κ B signaling pathway in esophageal adenocarcinoma cells.

Authors:  Rong Zhang; Xiaoran Yin; Haitao Shi; Jie Wu; Pramod Shakya; Dong Liu; Jun Zhang
Journal:  Dig Dis Sci       Date:  2013-10-05       Impact factor: 3.199

8.  Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus.

Authors:  Brooke M Winzer; Jennifer D Paratz; Marina M Reeves; David C Whiteman
Journal:  BMC Cancer       Date:  2010-06-16       Impact factor: 4.430

9.  Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death.

Authors:  John Thundyil; Sung-Chun Tang; Eitan Okun; Kausik Shah; Vardan T Karamyan; Yu-I Li; Trent M Woodruff; Stephen M Taylor; Dong-Gyu Jo; Mark P Mattson; Thiruma V Arumugam
Journal:  Exp Transl Stroke Med       Date:  2010-08-11

10.  Association of adiponectin multimers with Barrett's oesophagus.

Authors:  J H Rubenstein; J Y Kao; R D Madanick; M Zhang; M Wang; M B Spacek; J L Donovan; S D Bright; N J Shaheen
Journal:  Gut       Date:  2009-06-30       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.